Low molecular weight heparin (Logiparin) as thromboprophylaxis in elective abdominal surgery. A dose finding study. 1988

O Hauch, and L N Jørgensen, and T R Kølle, and H Nerstrøm, and O Schebye, and P Wille-Jørgensen, and P Ostergaard
Department of Surgery, Copenhagen Municipal Hospital, Denmark.

The efficacy and safety of a new not yet registered low molecular weight heparin (LMWH) (Logiparin) as thromboprophylactic agent was assessed in 51 patients undergoing major elective surgery. The patients were divided into three groups receiving either 2,500 anti-Xa international units (IU) (group 1), 50 IU per kg body weight (group 2) or 3,500 IU (group 3) subcutaneously once daily. All patients were screened with the 125I-fibrinogen uptake test, and whenever a FUT was abnormal or when clinical signs were present ascending phlebography was performed. Thrombosis occurred in 12.5% of the patients in group 1 and 0% of the patients in groups 2 and 3 (p greater than 0.05). In groups 1 and 2 only minor bleeding complications were recorded. In group 3 there was one haemorrhagic episode requiring interruption of the LMWH treatment. The optimal doses of this new LMWH seems to be in the range 2,500 IU-3,500 IU once daily. The final dose recommendation has to be established in large scale clinical trials.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D011516 Prothrombin A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia. Coagulation Factor II,Factor II,Blood Coagulation Factor II,Differentiation Reversal Factor,Factor II, Coagulation,Factor, Differentiation Reversal,II, Coagulation Factor
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006470 Hemorrhage Bleeding or escape of blood from a vessel. Bleeding,Hemorrhages
D006495 Heparin, Low-Molecular-Weight Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism. LMWH,Low-Molecular-Weight Heparin,Low Molecular Weight Heparin,Heparin, Low Molecular Weight

Related Publications

O Hauch, and L N Jørgensen, and T R Kølle, and H Nerstrøm, and O Schebye, and P Wille-Jørgensen, and P Ostergaard
May 1991, The Journal of bone and joint surgery. British volume,
O Hauch, and L N Jørgensen, and T R Kølle, and H Nerstrøm, and O Schebye, and P Wille-Jørgensen, and P Ostergaard
December 1986, Thrombosis and haemostasis,
O Hauch, and L N Jørgensen, and T R Kølle, and H Nerstrøm, and O Schebye, and P Wille-Jørgensen, and P Ostergaard
September 2007, Current opinion in pulmonary medicine,
O Hauch, and L N Jørgensen, and T R Kølle, and H Nerstrøm, and O Schebye, and P Wille-Jørgensen, and P Ostergaard
March 2019, The Cochrane database of systematic reviews,
O Hauch, and L N Jørgensen, and T R Kølle, and H Nerstrøm, and O Schebye, and P Wille-Jørgensen, and P Ostergaard
November 2018, The Cochrane database of systematic reviews,
O Hauch, and L N Jørgensen, and T R Kølle, and H Nerstrøm, and O Schebye, and P Wille-Jørgensen, and P Ostergaard
January 2009, The Cochrane database of systematic reviews,
O Hauch, and L N Jørgensen, and T R Kølle, and H Nerstrøm, and O Schebye, and P Wille-Jørgensen, and P Ostergaard
August 2019, The Cochrane database of systematic reviews,
O Hauch, and L N Jørgensen, and T R Kølle, and H Nerstrøm, and O Schebye, and P Wille-Jørgensen, and P Ostergaard
October 1991, Seminars in thrombosis and hemostasis,
O Hauch, and L N Jørgensen, and T R Kølle, and H Nerstrøm, and O Schebye, and P Wille-Jørgensen, and P Ostergaard
August 1996, The International journal of artificial organs,
O Hauch, and L N Jørgensen, and T R Kølle, and H Nerstrøm, and O Schebye, and P Wille-Jørgensen, and P Ostergaard
October 1990, Seminars in thrombosis and hemostasis,
Copied contents to your clipboard!